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Statins are very potent at lowering low-density lipoprotein (LDL) cholesterol. In patients
with established coronary artery disease, this reduction has been associated with con-
sistent clinical beneﬁt across the many large randomized trials conducted. In selected
patients without established disease but at high risk, particularly those with elevated
plasma concentrations of cholesterol, prolonged statin therapy has also been associ-
ated with impressive clinical beneﬁts. However, most of the studies conducted in these
populations have enrolled middle-aged patients, with few patients aged above 75 years.
Therefore, it is valid to question whether the beneﬁts achieved with statins in trials that
enrolled mostly relatively young patients can be extended to truly elderly patients.
Cholesterol is a strong risk factor for cardiovascular death and cardiovascular disease;
however, the relationship between cholesterol in the blood and cardiovascular mortality
is much stronger in younger than in older patients [1]. A joint analysis of the primary
prevention studies, entitled the Prospective Studies Collaboration, demonstrated that the
association between total cholesterol and the risk of ischaemic heart disease mortality is
age speciﬁc (Fig. 1). As expected, therefore, the impact of reducing cholesterol on the
risk of cardiovascular death is also age speciﬁc: with every 1-mmol/L reduction in total
Abbreviations: JUPITER, Justiﬁcation for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL,
low-density lipoprotein; NNT, number needed to treat; PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; 4S, Scandinavian
Simvastatin Survival Study.
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prevention and who derived clear beneﬁt from treatment,2
holesterol among patients aged 40—49 years, ischaemic
eart disease mortality is more than halved. In contrast,
he same reduction in those aged 80 years and older yields
reduction of only 15%. Because of this lower beneﬁt of
tatins in the elderly, questions have been asked about
hether the clinical beneﬁts observed with statins in young
nd middle-aged patients enrolled in randomized clinical
rials really extend to the elderly patients encountered in
outine clinical practice [2].
There is no question that statins are highly beneﬁcial
n preventing cardiovascular events and reducing cardio-
ascular mortality in secondary prevention in patients with
stablished cardiovascular disease, particularly coronary
rtery disease. This beneﬁt has been established consis-
ently by a host of randomized clinical trials, starting
ith the Scandinavian Simvastatin Survival Study (4S) in
he early 1990s and followed subsequently by similar trials
erformed in primary prevention in patients without estab-
ished cardiovascular disease but with elevated cholesterol
3—8]. More recently, the beneﬁt of a marked reduction
n cholesterol, even in patients with ‘normal’ cholesterol
oncentrations, was also seen in patients with high cardio-
ascular risk but no established disease in Justiﬁcation for
he Use of statins in Prevention: an Intervention Trial Evalu-
igure 1. Ischaemic heart disease mortality versus usual total choles
lsevier. CHD: coronary heart disease; MI: myocardial infarction; TIA: tra
b
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ting Rosuvastatin (JUPITER) [9]. Again, the question arises
f how this beneﬁt observed in secondary prevention and
n selected individuals in primary prevention is translated
nto the elderly patient population seen in routine clini-
al practice. In secondary prevention, a pooled analysis of
atients enrolled in randomized clinical trials with statins
nd aged above 65 years, published by Aﬁlalo et al. [10],
eported a 22% reduction in 5-year mortality with statin
se. However, among these studies, only one (PROspective
tudy of Pravastatin in the Elderly at Risk [PROSPER]) was
esigned speciﬁcally to examine the role of a statin (pravas-
atin) in the elderly, and that trial did fulﬁl its primary
oal, which was to demonstrate a reduction in the compo-
ite endpoint of cardiovascular death, myocardial infarction
nd stroke in elderly patients [11]. It is interesting, how-
ver, to note that pravastatin had no direct effect on stroke
n that trial. In addition, when the population from PROS-
ER was broken down as a function of prior risk, there was
very substantial group of patients who were in secondaryterol. Reprinted from [1], copyright (2007), with permission from
nsient ischaemic attack.
ut the primary prevention cohort (a little more than 60%
f the overall cohort) derived no apparent beneﬁt from
reatment (Fig. 2). More recently, a meta-analysis of ran-
omized controlled trials indicated beneﬁts of statins in
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wFigure 2. Effect of pravastatin according to primary or secondar
with permission from Elsevier. CHD: coronary heart disease; MI: my
people without established cardiovascular disease but with
cardiovascular risk factors, by showing a 30% reduction in
major coronary events and a 12% reduction in all-cause mor-
tality [12]. Moreover, the magnitude of cardiovascular risk
reduction (i.e., acute myocardial infarction, percutaneous
transluminal angioplasty or coronary artery bypass graft)
was proportional to the magnitude of LDL cholesterol reduc-
tion, even in elderly patients at high cardiovascular risk [13].
It is established, therefore, that statins are beneﬁcial
in primary and secondary prevention in most patients with
elevated cholesterol, but whether these beneﬁts extend to
the very elderly, particularly in primary prevention, is still
not entirely clear. In addition, there seems to be some dis-
parity between the effects that statins have on stroke, and
on cardiovascular death and myocardial infarction in the
elderly [11]. The recent presentation of JUPITER results
in the elderly gives us an opportunity to revisit the evi-
dence for the beneﬁts of statins in the elderly [9]. Indeed,
JUPITER did enrol a large fraction of patients aged above
75 years, and a prespeciﬁed analysis of the elderly has been
conducted and was presented at the latest European Soci-
ety of Cardiology meeting in Barcelona. What did JUPITER
tell us with respect to statins and the elderly? First, the
relative risk reduction from treatment with rosuvastatin
in JUPITER was smaller in older than in younger patients,
both for the primary endpoint (a composite of cardiovascu-
lar death, myocardial infarction, stroke and other events)
and for the triple composite endpoint of death, myocardial
infarction and stroke. However, because the risk is greater
in older than in younger patients, the absolute risk reduction
was also greater in older than in younger patients, regard-
less of the endpoints examined. For instance, the reduction
in cardiovascular death, myocardial infarction and stroke
per 100 patient-years was 0.34 for patients aged less than
70 years and 0.54 for patients aged 70 years and above. This
t
s
L
tvention status in PROSPER. Reprinted from [11], copyright (2002),
ial infarction; TIA: transient ischaemic attack.
reater absolute beneﬁt translates into a smaller number
f patients needed to treat (NNT) for older compared with
ounger patients. For 5 years of therapy, in order to avoid
ne component of the primary endpoint, the NNT was 19 for
he elderly compared with 29 for younger patients. To avoid
ne cardiovascular death, myocardial infarction or stroke,
he NNT was 29 for patients aged above 70 years and 55
or younger patients. These data are important. They are
erived from a large, contemporary, international, double-
lind, randomized study, and they provide evidence for the
linical beneﬁt of statins in primary prevention in the elderly
ith a large group of patients aged above 75 years. From this
tudy, we can see that the beneﬁt seen from rosuvastatin in
he overall trial is also seen in the elderly subgroup, and,
nterestingly, includes a reduction in stroke. While the rela-
ive reduction may be smaller with older than with younger
atients (Fig. 3), the absolute beneﬁt is actually higher
mong the elderly (Fig. 4). Importantly, there was no evi-
ence for a clear increase in risk of side effects with age,
hich therefore provides strong evidence for not depriving
lderly patients of the beneﬁts of statins. This is important
ecause all registries and surveys concur in demonstrating
hat there is underuse of statins in elderly patients in both
econdary and primary prevention [14,15].
There remain a number of caveats, however, as JUPITER
ertained to a very special population of high cardiovas-
ular risk patients with rather low LDL cholesterol values
ut selected on the basis of an elevated high-sensitivity
-reactive protein concentration; this therefore begs the
uestion of whether we can extend the results to patients
ith elevated LDL cholesterol. It is indeed paradoxical to
hink that we now have much stronger evidence for using
tatins in primary prevention in elderly patients with low
DL cholesterol than we have for a similar type of popula-
ion with elevated LDL cholesterol. There is no reason to
64
Figure 3. Relative risk reduction (as a percentage) from treat-
ment with rosuvastatin compared with placebo in younger patients
vs. older patients in JUPITER. Primary endpoint: composite of car-
diovascular (CV) death, myocardial infarction (MI), stroke and other
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npublished data presented at the European Society of Cardiology
ongress 2009
xpect that there would be less beneﬁt in patients with
igh LDL cholesterol, but this population simply has not
een studied in adequately powered trials. A second impor-
ant caveat is that the average age of the elderly patient
opulation enrolled in JUPITER was ‘only’ 74 years with an
nterquartile range of 72—78 years and, therefore, the rel-
vance of these results to very elderly patients aged above
0 years is still uncertain. In addition, it is well-known that
very elderly patient population encounters quite differ-
nt problems related to polypharmacy and a high level of
omorbidities, which may, in part, negate the beneﬁts of
igure 4. Absolute risk reduction from treatment with rosuvas-
atin in younger patients vs. older patients in JUPITER. Primary
ndpoint: composite of cardiovascular (CV) death, myocardial
nfarction (MI), stroke and other events.
npublished data presented at the European Society of Cardiology
ongress 2009.
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tatins. Clearly, further studies are needed to clarify the
ole of statins in the very elderly patient population.
In conclusion, there is no reason to deprive elderly
atients at high cardiovascular risk and with elevated
holesterol from the beneﬁts conferred by statin therapy.
hile the relative reduction in event rates achieved in older
atients may be lower than in younger patients, the abso-
ute beneﬁt (and, therefore, the number of events avoided)
s greater because the absolute risk is higher. Whether these
ndings apply to very elderly patients aged above 80 years
s still uncertain, given the problems related to preventive
olypharmacy in this speciﬁc patient subset.
onﬂict of interest
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